Wockhardt to introduce Kelocote to treat scars

10106 Investors following Wockhardt. Share this News with them.

0

Like this story, share it with millions of investors on M3

Wockhardt to introduce Kelocote to treat scars

Wockhardt to soon introduce Kelocote to treat scars

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Wockhardt opposes Roche patent on Pegasys Wockhardt to market painkiller in the US Buy Wockhardt; target of Rs 552: Sharekhan ALSO READ See latest News about Wockhardt See previous management interviews See what other Experts & Brokerages are saying about Wockhardt Wockhardt BSE | NSE 25/05/12 Are Mutual Funds betting on Wockhardt?

Pharmaceutical and biotechnology major Wockhardt Limited has signed an in-licensing agreement with Advanced Biotechnologies Inc. of US to market a patent-protected product to treat scars.

"Wockhardt is committed to cater to unmet medical needs of Indian patients," Wockhardt chairman Habil Khorakiwala said. "We will soon introduce a patented gel - Kelocote - to treat scars and keloids arising from accidents, burns, surgery and acne."

Kelocote is a unique silicone gel for scars arising from accidents, burns, surgery and acne as well as skin disorders such as dermatitis and varicella. It is also useful in treating keloids, which are fibrous growths formed over healed wounds. Kelocote is available as an easy-to-apply gel form with self-drying action.

While clinical trials on Indian patients are in progress, clinical data from various countries has already proven its efficacy and cost-effectiveness. Kelocote is currently marketed in North America, Europe, Australia and South-East Asia. Wockhardt plans to launch Kelocote in India in the third quarter of 2007.

Scars are a common but undermanaged problem. More than 100 million people acquire new scars each year in developed countries alone. Abnormal scars can be aesthetically distressing, disfiguring as well as psychologically disabling.

Last year, Wockhardt entered into an in-licensing deal with LSI of UK for Vitix, a patented product for the management of vitiligo (leucoderma) and with Crawford Healthcare of UK for Viticolor, a camouflage gel for vitiligo-affected skins.

Wockhardt Limited is an internationally approved pharmaceutical and biotechnology company having a strong and innovative research and development programme. Wockhardt has made four successful acquisitions in Europe, where it employs 850 people. It has a wholly-owned subsidiary in USA. Europe and USA together account for over half of Wockhardt's sales.

Sourced From: Corporate Voice|Weber Shandwick